AI
Sinclair Plans to Enter XPrize with Oral Rejuvenation Drug
Dr. David Sinclair of Harvard University is planning a human trial of an oral "reprogramming" drug, SL-100, within the framework of the XPrize competition. The attempt at whole-body rejuvenation sparks both hope and caution.